rnai沉默igf1r表达对宫颈癌hela细胞生长和药物敏感性的实验分析-experimental analysis of rnai silent igf1r expression on growth and drug sensitivity of cervical cancer hela cells.docxVIP

下载本文档

1
0
约9.04万字
约 10页
2018-06-01 发布于上海
举报
版权申诉

rnai沉默igf1r表达对宫颈癌hela细胞生长和药物敏感性的实验分析-experimental analysis of rnai silent igf1r expression on growth and drug sensitivity of cervical cancer hela cells.docx

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

rnai沉默igf1r表达对宫颈癌hela细胞生长和药物敏感性的实验分析-experimental analysis of rnai silent igf1r expression on growth and drug sensitivity of cervical cancer hela cells

PAGE PAGE VI RNAi 沉默 IGF-1R 表达对宫颈癌 Hela 细胞生长和药物敏感性的实验研究中文摘要基因有望成为宫颈癌基因治疗的一个有效靶点。关键词：RNAi；IGF-1R；宫颈癌；Hela 细胞；顺铂；药物敏感性作者：武炜指导老师：申咏梅英文摘要 RNAi 沉默 IGF-1R 表达对宫颈癌 Hela 细胞生长和药物敏感性的实验研究 The Experimental Study of Growth and Chemosensitivity Induced by RNA Interference to Silence IGF-1R Gene in Human Cervical Carcinoma Hela Cells Abstract AIM: The cervical carcinoma is one of the most common malignant tumors of the female genital tract, its incidence has more than colorectal cancer, next to breast cancer, ranking the second of the female malignancy. Now, the treatment of cervical carcinoma in traditional methods is surgery, radiotherapy and chemotherapy, but they have limit and obvious side-effect. In recent years, RNA interference (RNAi) technology has brought new hope for the treatment of cervical carcinoma. This research selected insulin-like growth factor 1 receptor (IGF-1R) which associated with the insulin-like growth factors (IGFs) signal transduction pathways as the object of study. Through using RNAi technology, we constructed the IGF-1R shRNA recombinant plasmid expression vectors and transfected them into human cervical carcinoma Hela cells. Then, we observed the growth of Hela cells and detected the sensitivity changes of combining with chemotherapy drug cisplatin stimulation by silencing IGF-1R gene in vivo and in vitro, which provided an experimental foundation for the further gene therapy study of cervical carcinoma. METHODS: ①According to the cDNA sequence of IGF-1R gene in GenBank, structure of IGF-1R mRNA was analyzed by software to select four targeted interference sites, and to design four interference sequences and a negative control sequence which were no homology with any other human genes. We established the recombinant plasmid vectors of IGF-1R shRNAs. After sequencing and restrictive enzyme digestion identification, recombinant plasmids were extracted for Hela cells’ transfection; ②The following experiments in